Evidence map›Paper›PMID 40229815›Full record

SynthesisEuropean journal of medical research2025

Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis.

Wenze Li, Sijing Kang, Yu Jiao, Pengjie Yue, Weilin Dong, Rui Ge, Ziyi Wang, Xiaojing Yan

Abstract readSystematic ReviewComparative StudyNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenze Li *Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Sijing Kang *Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yu JiaoDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Pengjie YueDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Weilin DongDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Rui GeDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Ziyi WangDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Xiaojing YanDepartment of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China. yanxiaojing_pp@hotmail.com.

Funding

Liaoning Province Central Guidance Special Project for Local Science and Technology Development 2023JH6/100200006the Xingliao Talents Program xlyc1807265Translational Research Grant of HCRCH 2020ZKMB06
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is the most common acute leukemia in adults, with a median age at diagnosis of 68 years. The outcomes in older or unfit AML patients on intensive chemotherapy are poor, and thus, it is necessary to explore alternative strategies. In recent years, non-intensive therapies have transformed the standard of care for this population. Despite the increasing number of randomized clinical trials (RCTs) and cohort studies in this area, the optimal treatment approach remains unclear.

methodsWe sourced four databases, PubMed, Embase, Cochrane, and Web of Science, until July 07, 2024, to identify all Phase II/III randomized controlled trials (RCTs) and cohort studies evaluating low-intensity treatments for older AML patients. Overall survival (OS), recurrence-free survival (RFS), complete remission (CR), complete remission with incomplete hematologic recovery (CRi), overall response rate (ORR), and adverse events (AEs) graded ≥ 3 were analyzed using a Bayesian fixed-effects network meta-analysis (NMA).

resultsA total of 4920 patients across 26 trials were included. In terms of improving OS, AZA + VEN, LDAC + glasdegib, and LDAC + VEN (SUCRA = 0.936, 0.898, and 0.718, respectively) were the most effective treatments. For CR, ORR, and CRi, AZA + VEN ranked highest among all therapies (SUCRA = 0.836, 0.911, and 0.829, respectively).

conclusionThis systematic review and network meta-analysis suggest that AZA + VEN is superior to the current standard of care, particularly in improving OS, CR, ORR, and CRi. LDAC + glasdegib also demonstrated promising efficacy and warrants further investigation.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteAgedBenzimidazolesHumansPhenylurea CompoundsRandomized Controlled Trials as TopicTreatment OutcomeBenzimidazolesPhenylurea CompoundsAcute myeloid leukemiaElderlyHypomethylating agentsNetwork meta-analysisVenetoclax

Identifiers

PMID40229815
PMCPMC11998139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.